COVID-19 Vaccine Update: According to the results of Russia’s Sputnik-V vaccine interim trial, Covid is 92 percent effective at protecting people from 19. According to a Reuters report, the country’s Sovereign Health Fund has said this on Wednesday. Russia is competing with Western countries over the vaccine. The Corona epidemic has killed more than 1.2 million people worldwide and has also caused a huge disaster to the economy.
The vaccine was registered in August
Russia registered its Covid-19 vaccine in August for the use of the people. It is the first country to do so. However, the approval was received before the commencement of a large-scale trial in September. According to the report, head of RDIF Kirill Dmitriev said that we are showing on the basis of data that we have a very effective vaccine. With this, he said that this is the kind of news about which vaccine developers will one day talk with their grandchildren.
Based on data from 16 thousand people
The Russian Direct Investment Fund (RDIF), which supports the vaccine and markets it to the world, said the interim results are based on data from 16,000 trial competitors who have taken both shots of the two-dose vaccine. The interim assessment was carried out after the 20 participants in the trial developed the Covid-19. This is substantially lower than the 94 infected trials of the vaccine being developed by Pfizer Inc PFE.N and BioNTech. To confirm its effective rate, Pfizer said that she would continue her trial till 164 Covid-19 cases are completed.
Covid 19 Vaccine: Preparing to launch Moderna vaccine, negotiating with WHO for supply
RDIF said in a statement that Russia’s trial would continue for six more months and the data from the trial would be published in a large international medical journal after review.